Clinical trial · Interventional
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carevive software | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Use of Carevive software
- description
- Reporting and management of side effects from oral targeted therapy or immunotherapy, through Carevive software, in patients who have advanced Renal Cell Carcinoma (RCC).
- interventionNames
- Other: Carevive software
Primary outcomes (5)
- measure
- Number of Participants Who Submitted at Least One Carevive Survey
- timeFrame
- From enrollment through 48 weeks
- description
- Number of participants who completed at least one Carevive survey at any time during the 48 week study period.
- measure
- Percentage of Carevive Surveys Completed Per Participant
- timeFrame
- From enrollment through 48 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of histologically confirmed renal cell carcinoma of any subtype with either pathological or radiographic evidence of metastatic disease * Greater than 18 years of age * A participating Wilmot Cancer Center oncologist has determined that candidate should be started on either oral targeted therapy or immunotherapy for treatment of their advanced RCC; this can be for first-line or any subsequent line therapy * Able to provide written informed consent * Proficient in the English language and self-reports as literate * Must have an active email address or access to a smart device on which text messages can be received Exclusion Criteria: * Women cannot be breast-feeding * Does not have regular access to the internet * Unable to come to the Wilmot Cancer Center for appointments every 3-4 months for routine visits with their primary oncologist * Subjects who were on the study previously will not be allowed to re-enroll in the event of a treatment change
References
Publications (0)
Data not yet available